Trastuzumab Modulates the Protein Cargo of Extracellular Vesicles Released by ERBB2<sup>+</sup> Breast Cancer Cells
Cancers overexpressing the ERBB2 oncogene are aggressive and associated with a poor prognosis. Trastuzumab is an ERBB2 specific recombinant antibody employed for the treatment of these diseases since it blocks ERBB2 signaling causing growth arrest and survival inhibition. While the effects of Trastu...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Membranes |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0375/11/3/199 |